Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor ( EGFR ) Mutations: A Multicenter, Phase II Trial
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.70137 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Huiyang Shi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clin…. Hauptthemen laut MEDLINE: Bevacizumab, Afatinib, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Hope Run Special Fund of Cancer Fundation of China, Beijing Xisike Clinical Oncology Research Fundation.
Abstract (Originalsprache)
Background
Studies indicated that afatinib combined with angiogenesis inhibitor may achieve promising efficacy in non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor ( EGFR ) mutations.
Methods
This is a multicenter, Phase II trial to explore the efficacy and safety of afatinib plus bevacizumab at first‐line setting for EGFR ‐mutant NSCLC patients. The primary end point was progression‐free survival (PFS). The secondary end point included objective response rate (ORR), disease control rate (DCR) and safety.
Results
Between July 11, 2020 and November 11, 2021, 54 treatment‐naïve NSCLC patients were enrolled in the afatinib plus bevacizumab combination cohort. Meanwhile, 81 NSCLC patients with EGFR mutations treated with first‐line afatinib monotherapy were retrospectively collected. The median follow‐up time was 26.6 months. No significant difference in PFS was observed between the afatinib plus bevacizumab combination cohort and the afatinib monotherapy cohort (14.5 vs. 12.2 months, HR 0.87, p = 0.15), confirmed by propensity score matching (PSM) analysis. Patients with pleural metastasis (HR 0.56, 95% CI: 0.32–0.98, p < 0.05) and uncommon EGFR mutations (HR 0.61, 95% CI: 0.25–1.47, p = 0.05) experienced longer PFS in the combination cohort. ORR in the combination cohort is more favorable than in the afatinib monotherapy cohort (77.8% vs. 42.0%, p < 0.05). Diarrhea was the most common treatment‐related adverse events (TRAEs). 11.1% (6/54) patients had grade ≥ 3 TRAEs when treated with afatinib plus bevacizumab.
Conclusion
Afatinib combined with bevacizumab is well tolerated with moderate efficacy among patients with NSCLC, which might be a prospective strategy for patients with uncommon EGFR mutations and pleural metastasis. Trial Registration www.chictr.org.cn
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Me…
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
- Peking University Cancer Hospital/Beijing Institute of Cancer Prevention and Treatment, Key Laboratory of Malignant Tumor Pathogenesis and Transformation Research of Ministry of Education, First Department of Thoracic C…
- Department of Oncology, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China.
- Department of Oncology, Luhe Hospital Affiliated to Capital Medical University, Beijing, China.
- National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of…
ORCID-Profile: Junling Li, Shi Jin, Minglei Zhuo, Yu Feng, Haohua Zhu, Yuankai Shi, Xingsheng Hu
Förderung
- Beijing Hope Run Special Fund of Cancer Fundation of China
- Beijing Xisike Clinical Oncology Research Fundation
Zitieren
APA
Shi, H., Wang, M., Li, J., Jin, S., Zhuo, M., Zhao, J., Zhang, H., Yang, M., Shi, Q., Qin, H., Dong, G., Lan, D., Dai, Z., Feng, Y., Zhu, H., Lu, J., Zhu, K., Shi, Y., & Hu, X. (2025). Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor ( EGFR ) Mutations: A Multicenter, Phase II Trial. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70137
Vancouver
Shi H, Wang M, Li J, Jin S, Zhuo M, Zhao J, et al. Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor ( EGFR ) Mutations: A Multicenter, Phase II Trial. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70137
BibTeX
@article{Shi2025,
author = {Shi, Huiyang and Wang, Miaohan and Li, Junling and Jin, Shi and Zhuo, Minglei and Zhao, Jun and Zhang, Hongxia and Yang, Meng and Shi, Qingfang and Qin, Haifeng and Dong, Guilan and Lan, Dongmei and Dai, Zhong and Feng, Yu and Zhu, Haohua and Lu, Jingyu and Zhu, Kai and Shi, Yuankai and Hu, Xingsheng},
title = {Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor ( EGFR ) Mutations: A Multicenter, Phase II Trial},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.70137}
}
EUVIMED